At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 2,387 enrolled
Drug / intervention
S-217622 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of S-217622 in the Prevention of Symptomatic SARS-CoV-2 Infection in Household Contacts of an Individual With Symptomatic COVID-19
In Brief
A Phase 3 clinical trial evaluating S-217622 and Placebo for SARS-CoV-2 Infection. Completed, enrolled 2,387 participants across 178 sites in 5 countries.
Detailed Summary
The purpose of this study is to measure the proportion of participants who are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (positive reverse transcription polymerase chain reaction \[RT-PCR\] test) and have coronavirus disease 2019 (COVID-19) symptom(s) with S-217622 tablets compared with placebo tablets in participants who are household contacts of an individual with symptomatic COVID-19.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSARS-CoV-2 Infection
CountriesArgentina, Japan, South Africa, United States, Vietnam
Collaborators--
Timeline
Phase 3CompletedFinished
202420252026
First PostedJun 2023
Enrollment StartJun 2023
Primary CompletionAug 2024
Study CompletionSep 2024
TodayJul 2026
First PostedJun 9, 2023
Enrollment StartJun 9, 2023
Primary CompletionAug 30, 2024
Study CompletionSep 18, 2024
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 3.1 years ago
Interventions
S-217622drug
Administered as a tablet.
Placebodrug
Administered as a tablet.